FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody containing only heavy chains, which binds to CD19. Also disclosed is a multispecific antibody which binds to CD19 and has binding affinity to CD3, a pharmaceutical composition containing said antibodies, method of treating diseases and conditions characterized by CD19 expression, including a B-cell disorder, use of said antibodies for treating a B-cell disorder and a kit for treating a disease or disorder characterized by CD19 expression.
EFFECT: invention provides antibodies containing only heavy chains, with binding affinity to CD19.
24 cl, 9 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| ANTI-CD19 ANTIBODIES AND METHODS FOR USE AND PRODUCTION THEREOF | 2021 |
|
RU2834996C1 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| ANTIBODY-LIKE BINDING PROTEINS WITH DOUBLE VARIABLE REGIONS HAVING CROSS-CROSS ORIENTATION OF BINDING REGIONS | 2012 |
|
RU2823693C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
